Nabriva Therapeutics Inc. (NBRV) stock gains during pre-market trading. Here’s what you should know?

Nabriva Therapeutics Inc. (NASDAQ: NBRV) stock plunged by 2.75% at the last close whereas the NBRV stock price rises by 3.77% in the pre-market trading session. Nabriva Therapeutics is a pharmaceutical business focused on the research and marketing of novel anti-infective drugs for the treatment of serious illnesses.

NBRV stock’ Update

Nabriva Therapeutics reported that it has reached a deal with Vizient to make XENLETA, which addresses community-acquired bacterial pneumonia (CABP), available to Vizient’s Pharmacy Network Program as a contracted product. With the purpose to enhance patient care and minimize costs, Vizient offers knowledge, analytics, and advisory services, as well as a contract portfolio totaling more than $110 billion in annual purchasing volume.

Nabriva CEO Ted Schroeder stated that,

They are encouraged by Vizient’s call to make XENLETA accessible to their Hospital Pharmacy Network, which will allow access across Vizient member hospitals, which account for more than half of all hospitals in the United States. According to data from the Healthcare Cost and Utilization Project, roughly 3 million adults are treated with CABP in hospitals each year. Furthermore, many of these individuals may be more susceptible to the side effects of respiratory fluoroquinolones or live in areas where macrolide resistance is common (>25 percent). They’re excited about the prospect of providing clinicians with a short-course, IV and oral monotherapy treatment method for their CABP patients that fulfills these healthcare problems.

Recent Development

In Taiwan, Nabriva Therapeutics’ partner, Sumitomo Pharmaceuticals (Suzhou) Co., has received clearance to sell XENLETA (lefamulin) oral and intravenous (IV) formulations for the cure of community-acquired pneumonia (CAP) in adults.

In May 2021, Nabriva signed a deal with Sumitomo Pharmaceuticals (Suzhou) which is a Chinese unit of Sumitomo Dainippon Pharma, for the development and commercialization of lefamulin in the Greater China Region. However, The exact date of XENLETA’s introduction in Taiwan is unclear.

Related posts